Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab in Hypermutated Recurrent Glioblastoma
NCT04145115Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2020
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in glioblastoma (GBM), astrocytoma, sponsored by National Cancer Institute. Started Dec 2020; status: active, not recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT04145115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145115.